Neurocrine Biosciences, Inc. (NBIX) — ESG & Values Scores

Environment story

Neurocrine Biosciences discloses minimal environmental data in its 10-K filing. Scope 1, Scope 2, and Scope 3 emissions are not reported. No net-zero target year is disclosed. The company does not highlight significant direct operational carbon footprint (as a biopharmaceutical firm with outsourced manufacturing), but complete absence of disclosed emissions metrics and climate commitments represents a material gap. No resource controversies, toxic-waste disputes, or water-consumption issues are identified in available filings. Without affirmative disclosure of renewable energy procurement, carbon-reduction initiatives, or net-zero targets, the company defaults to a moderate environmental score reflecting the lack of demonstrated commitment.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Outsourced Manufacturing Model

Company relies entirely on third-party manufacturers for INGREZZA, CRENESSITY, and product candidates, reducing direct operational carbon footprint.

Potential indirect emissions mitigation through reduced facility operations, though Scope 3 supply-chain emissions not quantified or publicly committed to reduction.

Social story

Neurocrine Biosciences reports a workforce of approximately 2,000 employees as of December 31, 2025, grown from ~200 in 2017, indicating rapid expansion. The company highlights Fortune recognition as a top-10 employer in biopharma for three consecutive years (2023–2025) and describes a mission-driven culture with annual employee engagement surveys, structured onboarding, professional development, and competitive compensation including equity grants, health insurance, 401(k) matching (dollar-for-dollar up to 6%), 12 weeks of paid parental leave, and ESPP. No CEO-to-worker pay ratio, diversity metrics (workforce/leadership gender/ethnicity breakdown), turnover rates, or union-standing information are disclosed in the 10-K. No labor disputes, NLRB complaints, or strikes are reported. Supply-chain human-rights audits or cobalt/lithium sourcing policies are not disclosed. The company demonstrates positive employment practices and cultural initiatives but lacks quantified DEI and labor-relations transparency.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Fortune Best Workplaces Recognition

Ranked among Fortune 'Best Workplaces in Biopharma' Top 10 for three consecutive years (2023–2025).

External validation of workplace culture and employee satisfaction; signals commitment to retention and engagement.
Annual Employee Engagement Survey

Confidential survey conducted annually to assess engagement, identify drivers of attrition/retention, and develop targeted action plans.

Data-driven human capital management; senior management and Board review results annually.
Comprehensive Benefits and Compensation

Market-driven base salaries, annual performance bonuses, equity grants (stock options/RSUs) for majority of employees, health insurance (medical/dental/vision), 401(k) matching (dollar-for-dollar up to 6%), 12 weeks paid parental leave, ESPP, flexible spending accounts, EAP.

Competitive total rewards designed to attract and retain talent; equity participation aligns employee and shareholder interests.
Professional Development Programs

Structured onboarding, continuous learning through professional development courses, competency-based workshops, and external leadership development facilitation.

Supports employee growth and retention; builds internal leadership pipeline.
Sales Force Expansion

October 2025 announcement of planned expansion of INGREZZA and CRENESSITY sales teams, with completion expected by end of Q1 2026.

Increases employment and commercial reach; demonstrates continued investment in workforce.

Governance story

Neurocrine Biosciences operates with a single-class common stock structure (no dual-class voting identified in 10-K). Board independence percentage is not disclosed in available filings. No active lobbying expenditures targeting climate deregulation or consumer-protection rollbacks are reported. In August 2025, the company received a civil investigative demand (CID) from the U.S. Department of Justice regarding sales and marketing of INGREZZA; the company is cooperating and states 'No assurance can be given as to the timing or outcome.' This represents an active regulatory investigation into compliance with anti-kickback, false-claims, and related healthcare statutes. The company describes a comprehensive compliance program designed to ensure business practices remain compliant with federal and state healthcare laws, HIPAA, Physician Payments Sunshine Act, and FCPA. No other material fines, SEC consent decrees, antitrust proceedings, or privacy violations are disclosed. The governance score reflects a lack of disclosed board-independence metrics, offset partially by the absence of dual-class share structures and a disclosed compliance framework, but penalized for the active DOJ investigation.

Criticisms on file

DOJ Civil Investigative Demand — INGREZZA Sales and Marketing Compliance
Source: NBIX 10-K 2025, Item 1A Risk Factors, Government Regulation section: 'In August 2025, we received a civil investigative demand from the U.S. Department of Justice (DOJ) requesting certain documents and information related to our sales and marketing of INGREZZA. We are cooperating with the DOJ's request. No assurance can be given as to the timing or outcome of the DOJ's investigation.'

Disclosed initiatives

Comprehensive Compliance Program

Company describes comprehensive compliance program designed to ensure business practices remain compliant with federal/state healthcare laws (Anti-Kickback Statute, false claims laws, HIPAA/HITECH, Physician Payments Sunshine Act, FCPA, import/export controls).

Intended to mitigate legal and regulatory risk; demonstrates governance structure for healthcare compliance.
Regulatory Cooperation

Company states it is 'cooperating with the DOJ's request' following August 2025 CID.

Demonstrates responsive posture to government investigation; outcome remains uncertain.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Neurocrine Biosciences, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Neurocrine Biosciences, Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)